NEW YORK (GenomeWeb) – Agilent Technologies said after the close of the market on Monday that it has received notice of an unsolicited mini-tender offer by TRC Capital to purchase up to 2.5 million shares of Agilent's common stock, or about .75 percent of the company's outstanding stock, at $41.55 per share. 

Agilent is advising its shareholders to reject the offer, saying that TRC Capital has acknowledged that its share price offer is more than 4 percent below the closing price of Agilent's shares on April 15, the last trading day before the mini-tender offer commenced. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.